Closing Thoughts on the Future of Advanced Cutaneous Squamous Cell Carcinoma

Dr Whitman closes the discussion by asking Dr In where he sees treatment of advanced cutaneous squamous cell carcinoma evolving and what developments he most hopes to see. Dr In reflects on the questions that remain unanswered, including how to select among the approved checkpoint inhibitors with better evidence, how to extend immunotherapy safely to solid organ transplant recipients and patients with autoimmune disease, and how to define the role of neoadjuvant treatment. The faculty discuss the importance of enrolling this population in prospective trials, given how frequently older and comorbid patients have been excluded from registrational studies. Both underscore the value of multidisciplinary collaboration among dermatology, surgical oncology, radiation oncology, and medical oncology in delivering these therapies well. Dr Whitman thanks Dr In for the discussion and closes the program for the OncLive audience.